PALI

Palisade Bio, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website alisadebio.com
Employees(FY) 12
ISIN US6963894026

Performance

-25.85%

-27.98%

-54.31%

-62.69%

-80.23%

YTD

-79.95%

Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.

Advanced Technical Analysis

Technical Analysis of PALI 2024-12-20

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 3 indicating strong downward pressure, while the Oscillators Score of 46 suggests a neutral stance, and the Technical Score of 25 reinforces the bearish outlook. This combination signals caution for potential investors, as the prevailing trend appears to b...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of PALI

Stock Rank

Recent News & Updates

2024-12-16 19:30
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board(Globenewswire)
2024-12-13 03:05
Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules(Globenewswire)
2024-12-11 23:05
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules(Globenewswire)
2024-12-02 19:15
Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects(Globenewswire)
2024-11-20 19:15
Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)(Globenewswire)
2024-11-13 20:00
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit(Globenewswire)
2024-11-11 19:45
Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108(Globenewswire)
2024-11-06 19:30
Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)(Globenewswire)
2024-10-30 20:30
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis(Globenewswire)
2024-10-14 20:00
Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting(Globenewswire)
2024-10-09 20:30
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)(Globenewswire)
2024-10-07 20:00
Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC(Globenewswire)
2024-09-24 20:00
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis(Globenewswire)
2024-09-15 20:00
Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies(Globenewswire)
2024-09-04 20:00
Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification(Globenewswire)
2024-08-18 20:00
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-08-12 20:05
Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-08-07 20:00
Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis(Globenewswire)
2024-07-30 21:15
Palisade Bio Participates in Virtual Investor What this Means Segment(Globenewswire)
2024-07-28 20:30
Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108(Globenewswire)
2024-07-18 20:30
Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108(Globenewswire)
2024-07-10 20:00
Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product(Globenewswire)
2024-06-23 21:00
Palisade Bio to Participate in the Virtual Investor Closing Bell Series(Globenewswire)
2024-06-20 20:15
Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences(Globenewswire)
2024-06-16 20:00
Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024(Accesswire)
2024-06-13 21:55
Bears are Losing Control Over Palisade Bio (PALI), Here's Why It's a 'Buy' Now(Zacks)
2024-06-10 20:30
Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108(Globenewswire)
2024-06-09 21:15
Palisade Bio to Present at the Virtual Investor Pitch Conference(Globenewswire)
2024-06-09 20:00
JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024(Accesswire)
2024-05-20 20:30
Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.